Neurocrine Biosciences NBIX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's accounts receivable?
- Neurocrine Biosciences (NBIX) reported accounts receivable of $768.1M in Q1 2026.
- How has Neurocrine Biosciences's accounts receivable changed year-over-year?
- Neurocrine Biosciences's accounts receivable increased by 48.9% year-over-year, from $516M to $768.1M.
- What is the long-term trend for Neurocrine Biosciences's accounts receivable?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's accounts receivable has grown at a 34.3% compound annual growth rate (CAGR), from $157.1M to $686.8M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.